<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<oembed>
  <author_name>marfan-info</author_name>
  <author_url>https://blog.hatena.ne.jp/marfan-info/</author_url>
  <blog_title>海外マルファン情報 | Global Marfan Updates</blog_title>
  <blog_url>https://marfan-info.hatenablog.com/</blog_url>
  <categories>
    <anon>オンラインセミナー</anon>
    <anon>血管型エーラス・ダンロス症候群（vEDS）</anon>
    <anon>循環器</anon>
    <anon>薬</anon>
  </categories>
  <description>Managing HTAD: Key Insights from the 2024 ESC Guidelines 42:12-43:27 Furthermore, for medical therapy, we advise Losartan, and why is this the case? This was a study done already in 2006, where it was shown that in mice, if you look at the aortic vessel wall, this is a normal aortic vessel wall in a…</description>
  <height>190</height>
  <html>&lt;iframe src=&quot;https://hatenablog-parts.com/embed?url=https%3A%2F%2Fmarfan-info.hatenablog.com%2Fentry%2F2025%2F03%2F10%2F225318&quot; title=&quot;2024 ECSガイドラインについて　〜ロサルタンと薬物療法について〜 - 海外マルファン情報 | Global Marfan Updates&quot; class=&quot;embed-card embed-blogcard&quot; scrolling=&quot;no&quot; frameborder=&quot;0&quot; style=&quot;display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;&quot;&gt;&lt;/iframe&gt;</html>
  <image_url></image_url>
  <provider_name>Hatena Blog</provider_name>
  <provider_url>https://hatena.blog</provider_url>
  <published>2025-03-10 22:53:18</published>
  <title>2024 ECSガイドラインについて　〜ロサルタンと薬物療法について〜</title>
  <type>rich</type>
  <url>https://marfan-info.hatenablog.com/entry/2025/03/10/225318</url>
  <version>1.0</version>
  <width>100%</width>
</oembed>
